Adjuvant Treatment in Colorectal Cancer
Author Information
Author(s): Taal B G, van Tinteren H, van t Veer L
Primary Institution: The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital
Hypothesis
Which patients will benefit the most from adjuvant therapy in colorectal cancer?
Conclusion
Preliminary data suggest that microsatellite instability (MSI) may serve as a significant prognostic marker for patients undergoing adjuvant treatment.
Supporting Evidence
- Chemotherapy provided maximal benefit in female patients and p53 normal tumours.
- MSI was almost exclusively found in colon cancer.
- LOH chr18 was present in two-thirds of colon cancer patients.
Takeaway
This study looks at how certain markers in cancer can help doctors decide which patients will do better with treatment.
Methodology
The study involved a random sample of patients with stage II and III colorectal cancer, examining the presence of molecular markers.
Limitations
The NACCP trial was stopped early, limiting the statistical power for subgroup analysis.
Participant Demographics
64 male and 53 female patients, with 57 in stage II and 59 in stage III.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website